Singapore-based biopharmaceutical company, Prestige Biopharma, and privately-owned pharma company, Alvogen, have entered a license and supply agreement to commercialise trastuzumab biosimilar (Hervelous) in central and eastern Europe.
More From BioPortfolio on "Companies agree to commercialise trastuzumab biosimilar in central and eastern Europe"